Rilotumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rilotumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target HGF
Clinical data
Legal status ?
Identifiers
CAS number 872514-65-3 N
ATC code None
UNII 51WEW898IJ YesY
Chemical data
Formula C6464H9932N1708O2010S46 
Mol. mass 145.2 kDa
 N (what is this?)  (verify)

Rilotumumab is a human monoclonal antibody designed for the treatment of solid tumors.[1]

Rilotumumab was developed by Amgen, Inc.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab". American Medical Association.